CardioExchange Archive

February 10th, 2015

Risk for Sudden Death in Spironolactone Users Who Take Trimethoprim-Sulfamethoxazole

Tony Antoniou, PharmD, PhD

Tony Antoniou discusses his case-control study of elderly residents of Ontario who were users of spironolactone and died suddenly within 14 days after receiving an antibiotic prescription.

---

April 14th, 2014

Selections from Richard Lehman’s Literature Review: April 14th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include TOPCAT, fibrinolysis for those with intermediate-risk PE, and more.

---

April 9th, 2014

Putting TOPCAT in Perspective

Bertram Pitt, MD, Marc A. Pfeffer, MD and Clyde Yancy, MD

TOPCAT investigators Bertram Pitt and Marc Pfeffer discuss the trial, and Clyde Yancy offers his analysis.

---

April 9th, 2014

TOPCAT Fails to Find Advantage for Spironolactone in HFPEF

Larry Husten, PHD

Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of […]

---

March 4th, 2013

Selections from Richard Lehman’s Literature Review: March 4th

Richard Lehman, BM, BCh, MRCGP

This week’s topic is the ALDO-DHF trial, which studied the effect of spironolactone on diastolic function and exercise capacity in patients with HF with preserved EF.

---

February 26th, 2013

Mixed Results for Spironolactone in Heart Failure with Preserved Ejection Fraction

Larry Husten, PHD

Although the mineralocorticoid receptor antagonists spironolactone and eplerenone have been shown to be beneficial in patients with heart failure (HF) with reduced ejection fraction (EF), their role in  HF patients with preserved EF has not been tested until now. Now the results of the Aldo-DHF study (Aldosterone Receptor Blockade in Diastolic Heart Failure), published in […]

---